Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seasonal influenza virus vaccine quadrivalent - Sanofi Pasteur

Drug Profile

Seasonal influenza virus vaccine quadrivalent - Sanofi Pasteur

Alternative Names: FluQuadri; FluQuadri Junior; Fluzone QIV ID; Fluzone QIV IM; Fluzone Quadrivalent; Fluzone Quadrivalent vaccine; High-Dose Influenza Vaccine Quadrivalent; Inactivated Quadrivalent Influenza Vaccine (Split Virion) influenza virus haemagglutinin; QIV; QIV-HD; Quadrivalent inactivated influenza virus vaccine; Quadrivalent influenza vaccine; Shenzhen quadrivalent influenza vaccine; Shz QIV; Vaxigrip QIV IM; VaxigripTetra

Latest Information Update: 20 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi K.K.; Sanofi Pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 22 Jul 2019 Sanofi plans a phase III trial for Influenza virus infections (Prevention) in October 2019 (IM) (NCT04024228) (EudraCT2019-000655-14)
  • 07 Jun 2019 Sanofi completes a phase I trial in Influenza virus infections (Prevention, In infants, In children, In adolescents, In adults, In the elderly) in China (IM) (NCT03430089)
  • 20 May 2019 Registered for Influenza virus infections (In adolescents, In children, Prevention, In adults, In infants) in Australia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top